Fishman Jay A Ltd. MI decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 709,510 shares of the biopharmaceutical company’s stock after selling 24,883 shares during the period. Pfizer comprises approximately 5.2% of Fishman Jay A Ltd. MI’s holdings, making the stock its 6th largest position. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $25,330,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Northstar Group Inc. boosted its position in shares of Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 35 shares in the last quarter. Peregrine Asset Advisers Inc. boosted its position in shares of Pfizer by 0.5% during the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in shares of Pfizer by 0.8% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 50 shares in the last quarter. River Wealth Advisors LLC boosted its position in shares of Pfizer by 0.3% during the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC boosted its position in shares of Pfizer by 0.5% during the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after purchasing an additional 57 shares in the last quarter. 69.74% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Inc. (PFE) opened at $36.54 on Friday. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $37.35. The company has a market cap of $217,800.00, a PE ratio of 22.42, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 earnings per share. sell-side analysts predict that Pfizer Inc. will post 2.59 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio is 78.53%.

Pfizer announced that its board has initiated a share repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Several equities analysts have recently weighed in on PFE shares. UBS Group set a $40.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. BMO Capital Markets restated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research report on Friday, November 10th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective for the company in a research report on Thursday, November 23rd. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $38.83.

In other news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock valued at $1,065,220 over the last three months. 0.06% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-holdings-reduced-by-fishman-jay-a-ltd-mi/1805277.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.